BackOdonate Therapeutics Overview

Odonate Therapeutics Total Current Liabilities

Track Odonate Therapeutics's total current liabilities ($30M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$30.30M
6.17% YoYΔ $1.76M vs prior year quarter

Peer average / median

Loading

Odonate Therapeutics Total Current Liabilities History

Loading

Odonate Therapeutics vs. peers: Total Current Liabilities Comparison

Loading

Odonate Therapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Odonate Therapeutics (ODT) FAQ

Odonate Therapeutics's total current liabilities stands at $30M as of September 2021. That compares with $29M in the prior-year period — up 6.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Odonate Therapeutics reported $30M in total current liabilities versus $29M a year earlier — a 6.2% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $29M in the prior-year period — up 6.2% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Odonate Therapeutics's total current liabilities evolved across reporting periods, while the comparison chart places ODT next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Odonate Therapeutics's reading of $30M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.